Loading data for PALI — first visit, this takes a few seconds.

알림

Palisade Bio Inc. (PALI)

NasdaqCM: PALI · 실시간 가격 · USD

2.10

+0.04 (1.94%)

종가 기준: Aug 21, 2026, 3:59 PM

2.10

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.94% (1D)

매수호가	1.54
시가총액	365.97M
매출 (ttm)	500K
순이익 (ttm)	-31.94M
	1.54
	0.65
	3.23
	-7.5
P/B (ttm)	3.00
P/S (ttm)	731.94
실적 발표일	n/a

매도호가	2.68
거래량	1,061,203
평균 거래량 (20일)	3,018,855
시가	2.09
전일 종가	2.06
일중 범위	2.08 - 2.13
52주 범위	0.53 - 2.86
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PALI 소개

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 30, 2007

직원 수 14

상장 거래소 NasdaqCM

티커 PALI

웹사이트 https://www.palisadebio.com

전체 기업 정보

재무 실적

2025년 Palisade Bio의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -16.78M로, 16.23% 증가했습니다.

재무제표

어닝 서프라이즈

Palisade Bio가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.05 예상치 하회 0.00, 및 92.75% 전년 대비 성장.

뉴스

3주 전 · Benzinga

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company...

1개월 전 · Stocktwits

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

3개월 전 · Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

3개월 전 · Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

3개월 전 · Insider Monkey

Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its cl...

2 페이지 중 1

Palisade Bio Inc. (PALI)